OECD validation of the Hershberger assay in Japan: Phase 3. Blind study using coded chemicals.
The Organization for Economic Co-operation and Development (OECD) has initiated the development of new guidelines for the screening and testing of potential endocrine disrupters. The Hershberger assay is one of the assays selected for validation based on the need for in vivo screening to detect androgen agonists or antagonists by measuring the response of five sex accessory organs and tissues of castrated juvenile male rats: the ventral prostate, the seminal vesicles with coagulating glands, the levator ani and bulbocavernosus muscle complex (LABC), Cowper's glands, and the glans penis. The Phase 1 feasibility demonstration stage of the Hershberger validation program has been successfully completed with a single androgen agonist and a single antagonist as reference substances. The Phase 2 validation study was performed, employing a range of additional androgen agonists and antagonists. Recently, the Phase 3 validation study was conducted and performed in several International laboratories. Three Japanese laboratories have contributed to the blind study using coded materials of Phase 3 validation. Four coded test substances in the agonistic version and seven substances in the antagonistic version were orally administered by gavage for 10 consecutive days, respectively. In the antagonist version of the assay, 0.2mg/kg/day of testosterone propionate (TP) was coadministered by subcutaneous injection. All five accessory sex reproductive organs and tissues consistently responded with statistically significant changes in weight within a narrow window in both versions. Therefore, the Japanese studies support the Hershberger assay as a reliable and reproducible screening assay for the detection of androgen agonistic and antagonistic effects.
Yamasaki
Kanji
K
Chemicals Evaluation and Research Institute, 3-822 Ishii, Hita, Oita 877-0061, Japan.
Ohta
Ryo
R
Okuda
Hirokazu
H
D000726:Androgen Antagonists / Q000145:classification / Q000633:toxicity*; D000728:Androgens / Q000819:agonists* / Q000145:classification; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D005062:European Union; D005837:Genitalia, Male / Q000187:drug effects* / Q000473:pathology; D007390:International Agencies; D007564:Japan; D008297:Male; D009919:Orchiectomy; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D016037:Single-Blind Method; D018675:Toxicity Tests / Q000379:methods / Q000592:standards*; D015262:Xenobiotics / Q000145:classification / Q000633:toxicity*
D000726:Androgen Antagonists; D000728:Androgens; D015262:Xenobiotics